Association Analysis of Dyslipidemia-Related Genes in Diabetic Nephropathy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  McKay, Gareth J ^a   Savage, David A ^b   Patterson, Christopher C ^a   Lewis, Gareth ^a   McKnight, Amy Jayne ^a   Maxwell, Alexander P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

APOC1 GENE; ARTICLE; CETP GENE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRELAND; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADOLESCENT; ADULT; APOLIPOPROTEIN C-I; CHILD; CHOLESTEROL ESTER TRANSFER PROTEINS; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IRELAND; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84875410718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058472     Document Type: Article

References (54)

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, et al. (2005) Report of the National Heart, Lung, and Blood Institute: National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111: 3489-3493.
2. Durrington PN, (1999) Diabetic dyslipidaemia. Baillieres Best Pract Res Clin Endocrinol Metab 13: 265-278.
3. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, et al. (2009) Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 32: 658-663.
4. Gu K, Cowie CC, Harris MI, (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281: 1291-1297.
5. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, et al. (1999) The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16: 466-471.
6. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsén T, Rastenyte D, et al. (1998) Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 41: 784-790.
7. The Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47: 1703-1720.
8. Parving HH, Hommel E, (1989) Prognosis in diabetic nephropathy. BMJ 299: 230-233.
9. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T, (1983) Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25: 496-501.
10. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, et al. (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17: 126-131.
11. Mulec H, Johnsen SA, Wiklund O, Bjorck S, (1993) Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22: 196-201.
12. Molitch ME, (2006) Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1: 1090-1099.
13. O'Brien T, Nguyen TT, Zimmerman BR, (1998) Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 73: 969-976.
14. Ginsberg HN, (2006) Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 91: 383-392.
15. Groop PH, Elliott T, Ekstrand A, Franssila-Kallunki A, Friedman R, et al. (1996) Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45: 974-979.
16. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, et al. (1989) Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 298: 487-490.
17. Watts GF, Naumova R, Slavin BM, Morris RW, Houlston R, et al. (1989) Serum lipids and lipoproteins in insulin-dependent diabetic patients with persistent microalbuminuria. Diabet Med 6: 25-30.
18. Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, et al. (2001) EURODIAB IDDM Complications Study. Plasma lipids and urinary albumin excretion rate in type 1 diabetes mellitus: The EURODIAB IDDM complications study. Diabet Med 18: 59-67.
19. Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, et al. (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29: 317-322.
20. Tolonen N, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, et al. (2008) Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 51: 12-20.
21. Taskinen MR, (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46: 733-749.
22. Krauss RM, Siri PW, (2004) Dyslipidemia in type 2 diabetes. Med Clin North Am 88: 897-909.
23. Solano MP, Goldberg RB, (2006) Management of dyslipidemia in diabetes. Cardiol Rev 14: 125-35.
24. Chahil TJ, Ginsberg HN, (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35: 491-510.
25. Mooradian AD, (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5: 150-159.
26. Heeringa P, Tervaert JW, (2002) Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 11: 287-293.
27. Keane WF (2000) The role of lipids in renal disease: future challenges. Kidney Int Suppl; 75: S27-S31.
28. Nishida Y, Yorioka N, Oda H, Yamakido M, (1997) Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 29: 919-930.
29. Kamanna VS, Roh DD, Kirschenbaum MA, (1998) Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus. Histol Histopathol 13: 169-179.
30. Kooner JS, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, et al. (2008) Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 40: 149-151.
31. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161-169.
32. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40(2):189-97. Erratum in: Nat Genet 40: 1384.
33. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56-65.
34. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 41: 47-55.
35. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713.
36. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, et al. (2010) Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42: 684-687.
37. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, et al. (2010) Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 30: 2264-2276.
38. Tukiainen T, Kettunen J, Kangas AJ, Lyytikäinen LP, Soininen P, et al. (2012) Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet 21: 1444-1455.
39. Kavanagh D, McKay GJ, Patterson CC, McKnight AJ, Maxwell AP, et al. (2011) Association analysis of Notch pathway signalling genes in diabetic nephropathy. Diabetologia 54: 334-338.
40. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, et al. (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 348: 2285-2293.
41. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, et al. (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58: 1403-1410.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329: 1456-1462. Erratum in: N Engl J Med 1993 330: 152.
43. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345: 851-860.
44. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345: 861-869.
45. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, et al. (2010) Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33: 1536-1543.
46. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, et al. (1993) Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb;13(6) 815-825: 43.
47. Weitgasser R, Galvan G, Malaimare L, Derflinger I, Hedegger M, et al. (2004) Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohort. Biomed Pharmacother; 58 619-627: 44.
48. Terán-García M, Després JP, Tremblay A, Bouchard C, (2008) Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding. Atherosclerosis; 196 455-460: 45.
49. Dullaart RPF, Sluiter WJ, (2008) Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics 9 747-763: 46.
50. Igl W, Johansson A, Wilson JF, Wild SH, Polasek O, et al. (2010) Modeling of environmental effects in genome-wide association studies identifies SLC2A2 and HP as novel loci influencing serum cholesterol levels. PLoS Genet;6(1) e1000798: 49.
51. Lahiry P, Cao H, Ban MR, Pollex RL, Mamakeesick M, et al. (2010) APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. J Lipid Res;51 843-848: 48.
52. McKnight AJ, Maxwell AP, Fogarty DG, Sadlier D, Savage DA, et al. (2009) Genetic analysis of coronary artery disease single-nucleotide polymorphisms in diabetic nephropathy. Nephrol Dial Transplant; 24 2473-2476: 47.
53. Danesh FR, Kanwar YS, (2004) Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J;18 805-815: 42.
54. Cardon LR, Bell JI, (2001) Association study designs for complex diseases. Nat Rev Genet. 2(2): 91-9.